Hydroxychloroquine: Completed Phase I enrollment

VG Life Sciences said investigators completed enrollment of about 24 patients with refractory or relapsed solid tumors in the open-label, dose-escalation, U.S. Phase I HSO1 trial evaluating once-daily oral HCQ plus twice-daily oral Nexavar sorafenib given on days 1-5 each week in a 28-day cycle. The fourth and final cohort is evaluating 400 mg HCQ plus twice-daily Nexavar. VG Life Sciences reported data from the third cohort in December (see BioCentury, Jan. 20). ...